Results 91 to 100 of about 67,145 (248)

A Hybrid Bioprinting–Microfabrication Approach to Controllable Multitype Spheroid Arrays for Modeling Tumor Heterogeneity

Advanced Healthcare Materials, EarlyView.
This work introduces a “cancer‐in‐a‐well” technology that recreates tumor heterogeneity in vitro using multitype spheroid arrays. Combining bioprinting/microdispensing with microstructured culture devices, the system improves drug screening and modeling of tumor complexity.
Simone Bonetti, Eva Clemente, Emanuela Mensà, Marco de Maria, Fulvia Farabegoli, Emanuela Saracino, Barbara Bortolani, Emanuela Marcelli, Renato Brandimarti, Dario de Biase, Giampaolo Zuccheri   +10 more
wiley   +1 more source

Developments in endoderm and pancreatic β-cell differentiation from human pluripotent stem cells [PDF]

Organoid
Human pluripotent stem cells (hPSCs) can differentiate into any cell type in the body, including cells or tissues from ectodermal, mesodermal, or endodermal lineages.
Dong Hyeon Lee, Hwajung Choo, Hyo Yi Choi, Sung Hwan Lee   +3 more
doaj   +1 more source

Advances in 3D Bioprinting for Breast Cancer Modeling: Tumor Microenvironment, Metastasis, and Drug Screening

Advanced Healthcare Materials, EarlyView.
Three‐dimensional bioprinting transforms breast cancer modeling from simple constructs into spatially organized, multicellular, perfused, and patient‐derived platforms. This review shows how bioinks, cellular composition, architecture, and flow govern tumor behavior and drug response, while revealing why complexity alone is insufficient without ...
Mustafa Nakipoglu, Mahboobeh Mahmoodi, Ehsanul Hoque Apu, Fahimeh Shahabipour, Sibel Emir Diltemiz, Sanjib Saha, Halima Alem, Nureddin Ashammakhi   +7 more
wiley   +1 more source

Advancements in brain organoid models for neurodegenerative disease research [PDF]

Organoid
Neurodegenerative diseases (NDs) such as Parkinson’s disease (PD) and Alzheimer’s disease (AD) are progressive disorders characterized by complex, human-specific pathology that poses challenges to drug discovery efforts. Traditional models, including two-
Soomin Park, Jong-Chan Park
doaj   +1 more source

Stretchable Microelectrode Arrays for Electro‐Mechanical Probing of Brain Spheroids

Advanced Healthcare Materials, EarlyView.
A multimodal device featuring kirigami‐patterned stretchable microelectrode arrays enables concurrent mechanical actuation and electrophysiological recording of brain spheroids. The platform supports multiple loading regimes and reveals mechanically induced modulation of spontaneous network activity in 3D neural tissue models.
Eleonora Martinelli, Ivan Furfaro, Flavius Timis, João Marques, Tala El Kaissi, Desirée Maulà, Laurine Kolly, Julian Bär, Sina Röllin, Scott Erickson, Laetitia Nikles, Benoît Delaup, Camille Delgrange, Loris Gomez Baisac, Luc Stoppini, Adrien Roux, Giuseppe Schiavone, Stéphanie P. Lacour   +17 more
wiley   +1 more source

Patient-derived organoids as a predictive platform for drug sensitivity in bladder cancer

Scientific Reports
Bladder cancer (BC) exhibits high inter- and intra-patient heterogeneity, limiting the efficacy of standard treatments and underscoring the need for personalized therapeutic models.
Shirin Hekmatirad, Fatemeh Gholizadeh, Saeed Montazeri, Laleh Sharifi, Mohammad Reza Nowroozi, Amir Ali Hamidieh, Mohammad Hosein Yazdi, Mahsa Mollapour Sisakht   +7 more
doaj   +1 more source

A clinician’s perspective: what tumor-organoid researchers ought to know [PDF]

Organoid
Patient-derived tumor organoids (PDTOs) provide powerful platforms for modeling human tumors, offering insights into cancer biology and personalized therapy development.
Jeong Uk Lim
doaj   +1 more source

Centralized intestinal organoid generation is a feasible and safe approach for personalized medicine as demonstrated in the HIT-CF Europe Organoid Study [PDF]

BACKGROUND: Patient-derived intestinal organoids (PDIOs) show great potential as in vitro drug testing platform for personalised medicine in Cystic Fibrosis and oncology.
HIT-CF organoid study group
core  

Cell‐Free DNA as a Biomarker of Cell Death and Treatment Response for On‐Chip Three‐Dimensional Tumor Models

Advanced Healthcare Materials, EarlyView.
This study presents quantifying cell‐free DNA (cfDNA) as a non‐disruptive and rapidly quantifiable method for assessing cell death for on‐chip 3D sarcoma tumor models. On‐chip cfDNA release reflects tumor burden, extent of cell death, and survival of in vitro and ex vivo 3D models, providing valuable insight into the temporal response of tumor models ...
Maryam Ziaee, Julie Lafontaine, Badr Id Said, Kousha Kamal, Kim Tsoi, Francis Rodier, Thomas Gervais, Philip Wong   +7 more
wiley   +1 more source

A rectal cancer organoid platform to study individual responses to chemoradiation

, 2019
Rectal cancer (RC) is a challenging disease to treat that requires chemotherapy, radiation and surgery to optimize outcomes for individual patients. No accurate model of RC exists to answer fundamental research questions relevant to patients.
Rectal cancer organoid platform
core